Vividion Therapeutics, Inc.

Vividion Therapeutics Initiates Phase I Trial of Novel RAS-PI3Kα Inhibitor for Advanced Solid Tumors

2 months ago

• Vividion Therapeutics has dosed the first patient in a Phase I trial of VVD-159642, an oral inhibitor targeting the RAS-PI3Kα pathway implicated in approximately 20% of all cancers. • The study will evaluate VVD-159642 as both monotherapy and in combination with sotorasib or trametinib in patients with advanced solid tumors, potentially offering a new treatment approach for RAS-driven cancers. • VVD-159642 represents Vividion's fourth clinical-stage program from its chemoproteomics platform, designed to selectively inhibit oncogenic signaling while avoiding toxicities that have limited previous attempts to target this pathway.